Meeting
2021 ASCO Annual Meeting
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
Authors
Seock-Ah Im
Seoul National University Hospital, Seoul, South Korea
Seock-Ah Im , Erika P. Hamilton , Antonio Llombart Cussac , Richard D. Baird , Johannes Ettl , Matthew P. Goetz , Hiroji Iwata , Anil Abraham Joy , Patrick Neven , Vincent Haddad , Andrew Stephen Walding , Manuel Selvi Miralles , Cynthia Huang Bartlett , Fabrice Andre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04711252
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS1101)
DOI
10.1200/JCO.2021.39.15_suppl.TPS1101
Abstract #
TPS1101
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Mafalda Oliveira
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2023 ASCO Annual Meeting
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.
First Author: Elisabeth Carola